Dongkook Pharmaceutical announced on the 18th that it had signed a contract to manufacture the finished product of ‘CP-COV03’, an oral antiviral drug for novel coronavirus infection (COVID-19) being developed by Hyundai Bioscience.
Dongkuk Pharmaceutical will carry out overall testing procedures, including the production of consigned production for the entire finished product, including the purchase of raw materials for CP-COV03 from Hyundai Bio, raw material testing, and product release testing.
Hyundai Bio submitted an application for a phase 2 clinical trial plan for CP-COV03 to the Ministry of Food and Drug Safety in January of this year and received approval on the 16th. Accordingly, the company plans to apply for emergency use approval after evaluating the safety and efficacy of mild and moderate COVID-19 patients.
Niclosamide, the main component of CP-COV03, is a component commonly used as an anthelmintic, and has a mechanism to block the proliferation of viruses by activating the autophagy of human cells, the host, during virus infection.
An official from Dongkuk Pharmaceutical said, “We have produced products with various formulation technologies and successfully performed major clinical samples and commercial production both internally and externally. said.
[ⓒ 세계일보 & Segye.com, 무단전재 및 재배포 금지]
